Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436177 | 1.00 | OPRK1 (0.35) | OPRK1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5728218 | 0.84 | CUL4A (0.33) | KMT2A | |
| SCHEMBL5728445 | 0.83 | — | — | |
| SCHEMBL15498328 | 0.83 | ALDH1A1 (0.33) | OPRK1ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL2157865 | 0.83 | ALDH1A1 (0.33) | OPRK1ALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL5438427 | 0.81 | PLAT (0.37) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL5438419 | 0.81 | PLAT (0.37) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL5728226 | 0.81 | — | — | |
| SCHEMBL5403021 | 0.80 | KDM4E (0.39) | ALDH1A1KDM4EHPGDHSD17B10TSHR | |
| SCHEMBL5403025 | 0.80 | KDM4E (0.39) | ALDH1A1KDM4EHPGDHSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007088148-A1 | DERIVATIVES OF THIOPHENE CARBOXILIC ACID AS ANTIVIRAL AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070099929-A1 | Substituted thiophenes | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099929-A1 | Substituted thiophenes | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099929-A1 | Substituted thiophenes | AICURIS GMBH & CO. KG (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099929-A1 | Substituted thiophenes | TPMT, HAVCR2, MTAP | OPRK1 1928/4885ALDH1A1 1246/4885KDM4E 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.